|
1
|
Ghoncheh M, Pournamdar Z and Salehiniya H:
Incidence and mortality and epidemiology of breast cancer in the
world. Asian Pac J Cancer Prev. 17:43–46. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Arnold M, Sierra MS, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global patterns and trends in
colorectal cancer incidence and mortality. Gut. 66:683–691. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ai Z, Lu Y, Qiu S and Fan Z: Overcoming
cisplatin resistance of ovarian cancer cells by targeting
HIF-1-regulated cancer metabolism. Cancer Lett. 373:36–44. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen Y, Han F, Cao LH, Li C, Wang JW, Li
Q, Zheng W, Guo ZX, Li AH and Zhou JH: Dose-response relationship
in cisplatin-treated breast cancer xenografts monitored with
dynamic contrast-enhanced ultrasound. BMC Cancer. 15:1362015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wahba HA and El-Hadaad HA: Current
approaches in treatment of triple-negative breast cancer. Cancer
Biol Med. 12:106–116. 2015.PubMed/NCBI
|
|
7
|
Son DJ, Hong JE, Ban JO, Park JH, Lee HL,
Gu SM, Hwang JY, Jung MH, Lee DW, Han SB and Hong JT: Synergistic
inhibitory effects of cetuximab and cisplatin on human colon cancer
cell growth via inhibition of the ERK-dependent EGF receptor
signaling pathway. Biomed Res Int. 2015:3975632015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xia M, Yu H, Gu S, Xu Y, Su J, Li H, Kang
J and Cui M: p62/SQSTM1 is involved in cisplatin resistance in
human ovarian cancer cells via the Keap1-Nrf2-ARE system. Int J
Oncol. 45:2341–2348. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xue LY, Chiu SM and Oleinick NL:
Staurosporine-induced death of MCF-7 human breast cancer cells: A
distinction between caspase-3-dependent steps of apoptosis and the
critical lethal lesions. Exp Cell Res. 283:135–145. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
del Solar V, Lizardo DY, Li N, Hurst JJ,
Brais CJ and Atilla-Gokcumen GE: Differential regulation of
specific sphingolipids in colon cancer cells during
staurosporine-induced apoptosis. Chem Biol. 22:1662–1670. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Manns J, Daubrawa M, Driessen S, Paasch F,
Hoffmann N, Löffler A, Lauber K, Dieterle A, Alers S, Iftner T, et
al: Triggering of a novel intrinsic apoptosis pathway by the kinase
inhibitor staurosporine: Activation of caspase-9 in the absence of
Apaf-1. FASEB J. 25:3250–3261. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Olguin-Albuerne M, Dominguez G and Morén
J: Effect of staurosporine in the morphology and viability of
cerebellar astrocytes: Role of reactive oxygen species and NADPH
oxidase. Oxid Med Cell Longev. 2014:6783712014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Marullo R, Werner E, Degtyareva N, Moore
B, Altavilla G, Ramalingam SS and Doetsch PW: Cisplatin induces a
mitochondrial-ROS response that contributes to cytotoxicity
depending on mitochondrial redox status and bioenergetic functions.
PLoS One. 8:e811622013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhaleh H, Azadbakht M and Pour Bidmeshki
A: Possible involvement of calcium channels and plasma membrane
receptors on Staurosporine-induced neurite outgrowth. Bosn J Basic
Med Sci. 12:20–25. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang XD, Gillespie SK and Hersey P:
Staurosporine induces apoptosis of melanoma by both
caspase-dependent and -independent apoptotic pathways. Mol Cancer
Ther. 3:187–197. 2004.PubMed/NCBI
|
|
16
|
Gil J, Almeida S, Oliveira CR and Rego AC:
Cytosolic and mitochondrial ROS in staurosporine-induced retinal
cell apoptosis. Free Radic Biol Med. 35:1500–1514. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xiong Z, Fu Z, Shi J, Jiang X and Wan H:
HtrA1 down-regulation induces cisplatin resistance in colon cancer
by increasing XIAP and activating PI3K/Akt pathway. Ann Clin Lab
Sci. 47:264–270. 2017.PubMed/NCBI
|
|
18
|
Cataldo A, Cheung DG, Balsari A, Tagliabue
E, Coppola V, Iorio MV, Palmieri D and Croce CM: miR-302b enhances
breast cancer cell sensitivity to cisplatin by regulating E2F1 and
the cellular DNA damage response. Oncotarget. 7:786–797. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen J, Solomides C, Parekh H, Simpkins F
and Simpkins H: Cisplatin resistance in human cervical, ovarian and
lung cancer cells. Cancer Chemother Pharmacol. 75:1217–1227. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Eckstein N: Platinum resistance in breast
and ovarian cancer cell lines. J Exp Clin Cancer Res. 30:912011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang J and Wu GS: Role of autophagy in
cisplatin resistance in ovarian cancer cells. J Biol Chem.
289:17163–17173. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Aquino A, Prete SP, Baier S, Cappelletti
D, Greiner JW, De Vecchis L, Graziani G and Bonmassar E:
Staurosporine increases carcinoembryonic antigen expression in a
human colon cancer cell line. J Chemother. 12:167–172. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Aquino A, Prete SP, Balduzzi A, Formica V,
Fossile E, Bonmassar L, Concolino F, Bonmassar E and Graziani G:
Treatment of peripheral blood with staurosporine increases
detection of circulating carcinoembryonic antigen positive tumor
cells. Int J Cancer. 100:119–121. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yan XY, Zhang Y, Zhang JJ, Zhang LC, Liu
YN, Wu Y, Xue YN, Lu SY, Su J and Sun LK: p62/SQSTM1 as an
oncotarget mediates cisplatin resistance through activating
RIP1-NF-κB pathway in human ovarian cancer cells. Cancer Sci.
108:1405–1413. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Brozovic A, Ambriovic-Ristov A and Osmak
M: The relationship between cisplatin-induced reactive oxygen
species, glutathione, and BCL-2 and resistance to cisplatin. Crit
Rev Toxicol. 40:347–359. 2010. View Article : Google Scholar : PubMed/NCBI
|
